Verona Pharma GAAP EPS of -$0.05 beats by $0.30

• Verona Pharma press release (NASDAQ:VRNA): Q4 GAAP EPS of -$0.05 beats by $0.30.
• Cash and cash equivalents at December 31, 2021, were $148.4 M (December 31, 2020: $188.0M).
• We believe our cash and cash equivalents at December 31, 2021, expected cash receipts from the U.K. tax credit program and funding expected to become available under our $30.0M debt facility, will enable us to fund our planned operating expenses and capital expenditure requirements through at least the end of 2023.